I-T dept detects Rs 550-cr hidden income after raids on Hetero pharma group

The Income Tax Department detected “unaccounted” income of Rs 550 crore and seized over Rs 142 crore cash after it recently raided Hyderabad-based Hetero pharmaceutical group, official sources claimed on Saturday.

Company officials were not immediately available for comments.

The raids were carried out by the tax department on October 6 at about 50 locations in half-a-dozen states.

“During the search, several bank lockers have been found, out of which 16 lockers have been operated. The searches have resulted in the seizure of unexplained cash amounting to Rs 142.87 crore, so far,” the Central Board of Direct Taxes (CBDT) said in a statement.

“Unaccounted income unearthed is estimated to be in the range of about Rs 550 crore till now,” it said.

Official sources identified it as the Hetero pharma group of Hyderabad.

Further investigations and quantification of undisclosed income detected is in progress, it added.

The CBDT frames policy for the Income Tax Department.

The CBDT said the group is engaged in the business of manufacturing of intermediates, active pharmaceutical ingredients (APIs) and formulations and majority of the products are exported to countries like the US and Dubai, and some African and European countries.

“Issues relating to discrepancies in purchases made from bogus and non-existent entities and artificial inflation of certain heads of expenditure were detected. Further, evidence of on-money payment for purchase of lands was also found,” it claimed.

Various other legal issues were also identified such as personal expenses being booked in the company’s books and land purchased by related parties “below government registration value.”

It alleged that hideouts were identified during the raids where second set of books of accounts and cash were found.

“Incriminating evidence in the form of digital media, pen drives, documents, etc. have been found and seized and digital “evidences” were gathered from SAP and ERP software maintained by the assessee group,” it said.

Hetero shot into limelight after the group signed several agreements and undertook development of various drugs such as Remdesivir and Favipiravir to treat COVID-19.

It has over 25 manufacturing facilities located in India, China, Russia, Egypt, Mexico and Iran.

The company last month had said that it had received Emergency Use Authorisation from the Drug Controller General of India (DCGI) for its biosimilar version of Tocilizumab for treatment of COVID-19 in hospitalised adults.

The Rs 7,500 crore pharma major is one of the firms that has tied up with Russian Direct Investment Fund to manufacture COVID-19 vaccine Sputnik V in India.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor